4basebio (LON:4BB) Trading 0.1% Higher – Here’s Why

4basebio PLC (LON:4BB) rose 0.1% during mid-day trading on Monday . The stock traded as high as GBX 1,170 ($15.12) and last traded at GBX 1,093 ($14.12). Approximately 680 shares traded hands during mid-day trading, a decline of 6% from the average daily volume of 727 shares. The stock had previously closed at GBX 1,092 ($14.11).

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a GBX 1,600 ($20.67) price target on shares of 4basebio in a report on Thursday, March 13th.

4basebio Price Performance

The stock has a market cap of £140.01 million, a P/E ratio of -1,401.28 and a beta of 1.09. The business has a 50-day simple moving average of GBX 1,151.99 and a 200 day simple moving average of GBX 1,246.71. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47.

Insider Buying and Selling

In other news, insider Amy Walker bought 1,151 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were acquired at an average price of GBX 1,120 ($14.47) per share, for a total transaction of £12,891.20 ($16,657.45). 68.44% of the stock is owned by insiders.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.